Telehealth company Ro launched a new tracker to help patients find a popular class of weight loss and diabetes drugs called GLP-1s amid shortages of those treatments in the U.S. The tool could be ...

GLP-1s have exploded in popularity, to the where, a ccording to the Kaiser Family Foundation, 12% of adults has taken Ozempic or another GLP-1 drug. Not surprisingly, this has led to a worldwide ...

Ro is a digital health platform designed to offer convenient access to healthcare services and products from the comfort of your home. Launched to revolutionize telehealth, Ro connects individuals ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded GLP-1s on the market. The tracker allows patients to self-identify, ...

The supply tracker could be a valuable tool for many Americans scrambling to get their hands on GLP-1s, such as Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic. Demand for those ...